Onderneming Novartis AG London S.E.

0QM7

CH0038459415

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per activiteit

Verkoop per regio

Ratings voor Novartis AG

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Farmaceutische producten - Andere

Beurs gesloten - London S.E. Andere beurzen 17:59:30 21-05-2018			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
76,86 ^CHF	-1,00%		-0,77%	-.--%

16/05	Dpa-AFX Overzicht: BEDRIJVEN van 16.05.2024 - 15:15	DP
16/05	Novartis overnamebod op MorphoSys overschrijdt minimum aanvaardingsdrempel	MT

Novartis AG is een van 's werelds leiders op het gebied van het ontwerpen, produceren en op de markt brengen van farmaceutische producten. De netto-omzet (exclusief beëindigde bedrijfsactiviteiten) kan als volgt worden uitgesplitst naar therapeutisch gebied
- oncologie (29,9%)
- immunologie (17,2%)
- cardiovasculaire, nier- en metabolische ziekten (14,1%);
- neurowetenschap (8,9%).
De resterende netto-omzet (29,9%) is afkomstig van contractproductie van farmaceutische producten.
Eind 2023 had Novartis AG wereldwijd 33 productielocaties.
De netto-omzet is geografisch als volgt verdeeld: Europa (33%), de Verenigde Staten (39,5%), Azië/Afrika/Australië (20,5%), Canada en Latijns-Amerika (7%).

CHF in miljoen	2022	Gewicht	2023	Gewicht	Delta
Established Brands 30,0 %	-	-	12 238	30,0 %	-
Oncology 29,9 %	-	-	12 213	29,9 %	-
Immunology 17,2 %	-	-	7 008	17,2 %	-
Cardiovascular, Renal and Metabolic 14,1 %	-	-	5 743	14,1 %	-
Neuroscience 8,9 %	-	-	3 633	8,9 %	-

CHF in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 39,5 %	16 860	34,9 %	16 139	39,5 %	-4,28%
Europe 18,9 %	10 469	21,7 %	7 704	18,9 %	-26,41%
Asia/Africa/Australasia 9,1 %	4 975	10,3 %	3 700	9,1 %	-25,63%
Germany 7,4 %	4 086	8,5 %	3 026	7,4 %	-25,94%
China 7,2 %	2 987	6,2 %	2 936	7,2 %	-1,73%
Canada and Latin America 7,0 %	3 709	7,7 %	2 854	7,0 %	-23,04%
Japan 4,2 %	2 106	4,4 %	1 729	4,2 %	-17,90%
France 3,8 %	2 156	4,5 %	1 572	3,8 %	-27,09%
Switzerland 2,9 %	926	1,9 %	1 175	2,9 %	+26,88%

Managers	Titel	Leeftijd	Van
Vasant Narasimhan CEO	Chief Executive Officer	48	01-01-05
Harry Werner Kirsch DFI	Director of Finance/CFO	59	01-01-03
Shreeram Aradhye CTO	Chief Tech/Sci/R&D Officer	62	16-05-22
Steffen Lang COO	Chief Operating Officer	57	01-04-17
Klaus Moosmayer CMP	Compliance Officer	56	01-12-18
Samir Shah IRO	Public Communications Contact	63	01-01-04
Simon Brown PRN	Corporate Officer/Principal	-	01-08-13
Kees Roks AUD	Comptroller/Controller/Auditor	61	01-05-22
Linda Kanitra PRN	Corporate Officer/Principal	-	-
Robert Kowalski HRO	Human Resources Officer	56	01-09-21

Besturend	Titel	Leeftijd	Van
Bill Winters BRD	Director/Board Member	62	01-01-13
Simon Moroney BRD	Director/Board Member	65	28-02-20
Hans Jörg Reinhardt CHM	Chairman	68	01-01-13
John Young BRD	Director/Board Member	60	07-03-23
Bridgette Heller BRD	Director/Board Member	62	28-02-20
Ton Büchner BRD	Director/Board Member	59	01-01-16
Charles Sawyers BRD	Director/Board Member	65	01-01-13
Nancy Andrews BRD	Director/Board Member	65	01-01-15
Patrice Bula BRD	Director/Board Member	68	28-02-19
Frans van Houten BRD	Director/Board Member	64	28-02-17

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	1	2 189 930 497	1 866 336 959 ( 85,22 %)	233 443 766 ( 10,66 %)	85,22 %

Naam	Aandelen	%	Totale waarde
NOVARTIS AG 6,625 %	145 083 991	6,625 %	14 087 M CHF
Sandoz Family Foundation 4,070 %	89 135 960	4,070 %	8 655 M CHF
UBS Asset Management Switzerland AG 3,123 %	68 391 910	3,123 %	6 640 M CHF
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0,3011 %	6 593 896	0,3011 %	640 M CHF
State Street Global Advisors Ltd. 0,2009 %	4 399 160	0,2009 %	427 M CHF
UBS AG (Investment Management) 0,1782 %	3 902 170	0,1782 %	379 M CHF
MFS International (UK) Ltd. 0,1780 %	3 899 024	0,1780 %	379 M CHF
La Mondiale SAM (Investment Portfolio) 0,1776 %	3 888 630	0,1776 %	378 M CHF
MFS International Singapore Pte. Ltd. 0,1715 %	3 755 587	0,1715 %	365 M CHF
Union Investment Privatfonds GmbH 0,1659 %	3 632 402	0,1659 %	353 M CHF

Naam	Aandelen	%	Totale waarde
PRIMECAP Management Co. 0,5670 %	12 417 755	0,5670 %	1 230 M CHF
Dodge & Cox 0,5641 %	12 353 985	0,5641 %	1 224 M CHF
Eaton Vance Management 0,3314 %	7 258 381	0,3314 %	719 M CHF
Dimensional Fund Advisors LP 0,2748 %	6 018 082	0,2748 %	596 M CHF
Loomis, Sayles & Co. LP 0,2702 %	5 917 972	0,2702 %	586 M CHF
Fiduciary Trust Company International 0,2603 %	5 700 550	0,2603 %	565 M CHF
U.S. Trust Company of Delaware 0,2273 %	4 977 839	0,2273 %	493 M CHF
Wellington Management Co. LLP 0,2096 %	4 589 350	0,2096 %	455 M CHF
Wells Fargo Bank NA 0,1826 %	3 997 877	0,1826 %	396 M CHF
The Ayco Co. LP 0,1397 %	3 059 361	0,1397 %	303 M CHF

Naam	Aandelen	%	Totale waarde
LUKB Expert Fondsleitung AG -	64 694	-	6 M CHF
ATP Fondsmaeglerselskab A/S -	46 082	-	5 M CHF
Swiss Rock Asset Management AG -	19 614	-	2 M CHF
Niederer & Partners AG -	5 300	-	517 893 CHF
JPMorgan Asset Management (China) Co Ltd. -	2 652	-	259 142 CHF
Liontrust Portfolio Management Ltd. -	474	-	46 317 CHF

Naam	Aandelen	%	Totale waarde
NOVARTIS AG 6.63%	145 083 991	6.63%	14 086 822 744 $
SANDOZ GROUP AG 4.30%	18 524 209	4.30%	629 154 567 $
MORPHOSYS AG 11.56%	4 360 100	11.56%	308 626 844 $
NOVARTIS INDIA LIMITED 70.68%	17 450 680	70.68%	216 480 572 $
THIRD HARMONIC BIO, INC. 6.48%	2 642 762	6.48%	27 643 291 $
ERASCA, INC. 8.12%	12 307 692	8.12%	23 138 461 $
OCULIS HOLDING AG 4.68%	1 713 521	4.68%	20 476 576 $
MOLECULAR PARTNERS AG 4.78%	1 739 130	4.78%	6 238 607 $
PRECISION BIOSCIENCES, INC. 5.98%	413 581	5.98%	4 020 007 $
GAMIDA CELL LTD. 2.82%	4 336 759	2.82%	78 062 $

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com

Naam	Categorie en sector
Novartis International AG Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis BioVenturesAG Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland.	Investment Managers
NOVARTIS INDIA LIMITED	Pharmaceuticals: Major
Novartis Securities Investment Ltd. Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The company is located in Bermuda.	Investment Managers
EBEWE Pharma Ges.m.b.H. Nfg.KG EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria.	Pharmaceuticals: Major
Novartis Capital Corp. Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ.	Finance/Rental/Leasing
Novartis Finance SA	Finance/Rental/Leasing
Sandoz GmbH Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria.	Pharmaceuticals: Major
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Holding AG Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment.	Financial Conglomerates
Novartis UK Pension Scheme	Investment Managers
Novartis Investments SARL Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg.	Financial Conglomerates
Novartis Investment Ltd.
Novartis Healthcare Pvt Ltd. Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar.	Pharmaceuticals: Major
Alcon Ophthalmika GmbH
Novartis Investment Ltd. (2120)
Novartis Services, Inc.
Sandoz Pvt Ltd. Sandoz Pvt Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz Pvt Ltd. is an Indian company that develops, manufactures and markets generic pharmaceutical products. The company is based in Mumbai, India and was founded in 1995.	Pharmaceuticals: Generic
Novartis Pharma GmbH Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.	Pharmaceuticals: Major

Trading rating

Beleggingsrating

ESG Refinitiv

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Accumuleren

Aantal analisten

Laatste slotkoers

102,9 USD

Gemiddelde koersdoel

107,9 USD

Spread / Gemiddelde doel

+4,91%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Farmaceutische producten - Andere

	Vaira. 1 jan.	Kapi.
ELI LILLY AND COMPANY	+32,09%	693 mld.
NOVO NORDISK A/S	+29,39%	584 mld.
JOHNSON & JOHNSON	-1,34%	372 mld.
MERCK & CO., INC.	+20,34%	332 mld.
ABBVIE INC.	+7,39%	294 mld.
ASTRAZENECA PLC	+14,25%	239 mld.
ROCHE HOLDING AG	-3,03%	211 mld.
AMGEN INC.	+8,49%	168 mld.
PFIZER, INC.	-0,52%	162 mld.

Farmaceutische producten - Andere